Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CDC25B | P30305 | 3/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | ME2 | P23368 | 1/20 | 0.50 |
| ▸ | ME1 | P48163 | 1/20 | 0.50 |
| ▸ | ME3 | Q16798 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthracene-9-Carboxylic Acid SCHEMBL122832 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL28099540 | 0.98 | MEN1 (0.95) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL11788252 | 0.98 | MEN1 (0.95) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL7054301 | 0.98 | MEN1 (0.95) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL28121546 | 0.98 | MEN1 (0.95) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL27733356 | 0.98 | MEN1 (0.95) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL28243282 | 0.96 | MEN1 (0.91) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| SCHEMBL4896934 | 0.92 | ALDH1A1 (0.84) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL28344339 | 0.90 | KDM4E (0.81) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL4342938 | 0.88 | KMT2A (0.78) | MEN1KMT2ACYP1A2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075733-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137796-A1 | PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2026-05-21 | — | — | US | claimed |
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4740956-A1 | PHARMACEUTICAL COMBINATION FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090071-A1 | CD19/CD38 MULTISPECIFIC ANTIBODIES FOR AUTOIMMUNE AND INFLAMMATORY THERAPIES | Biograph 55, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4717707-A2 | VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS | Alpine Immune Sciences, Inc. (US) | 2026-04-01 | — | — | EP | claimed |
| US-20260070963-A1 | MONOVALENT ANTI-PROPERDIN ANTIBODIES AND ANTIBODY FRAGMENTS | ALEXION PHARMA INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4706777-A2 | CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | Alpine Immune Sciences, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260062456-A1 | PD-L1 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | ALPINE IMMUNE SCIENCES INC (US) | 2026-03-05 | — | — | US | claimed |
| US-20260015415-A1 | PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION | argenx BV (BE) | 2026-01-15 | — | — | US | claimed |
| US-20220227833-A1 | CD80 VARIANT PROTEINS AND USES THEREOF | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2022-07-21 | — | — | US | claimed |
| EP-4027978-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC BIOLOGICS FOR TREATMENT OF DISEASE | Elektrofi, Inc. (US) | 2022-07-20 | — | — | EP | claimed |
| CN-114594265-A | Kit for detecting inflammatory bowel disease | 湖南携光生物技术有限公司 | 2022-06-07 | — | — | CN | claimed |
| WO-2022109335-A1 | GLYCOSIDE DUAL-CLEAVAGE LINKERS FOR ANTIBODY-DRUG CONJUGATES | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-05-27 | — | — | WO | claimed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2022087634-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3972960-A1 | CRYSTALLINE FORMS OF A BTK INHIBITOR | Novartis AG (CH) | 2022-03-30 | — | — | EP | claimed |
| US-20220088279-A1 | EXTRACORPOREAL DEVICES FOR METHODS FOR TREATING DISEASES ASSOCIATED WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES | GAMBRO LUNDIA AB (SE) | 2022-03-24 | — | — | US | claimed |
| EP-3423059-B1 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2022-03-23 | — | — | EP | claimed |
| CN-114188515-A | Polymer-coated high-nickel ternary cathode material and preparation method and application thereof | 厦门大学 | 2022-03-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062456-A1 | PD-L1 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | CD274, PDCD1LG2, PDCD1 | MEN1 2131/4885KMT2A 1762/4885CYP1A2 4511/4885 |
| US-20260137796-A1 | PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | TOP2B, TOP1, TOP2A | MEN1 3308/4885KMT2A 1883/4885CYP1A2 379/4885 |
| US-20260070963-A1 | MONOVALENT ANTI-PROPERDIN ANTIBODIES AND ANTIBODY FRAGMENTS | C1QBP, C9, C1S | MEN1 294/4885KMT2A 3577/4885CYP1A2 4723/4885 |
| US-20260015415-A1 | PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION | FCGRT, FCGR2A, FCGR1A | MEN1 1214/4885KMT2A 1451/4885CYP1A2 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.